Business Description
Cartesian Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8162123025
Total Employee Number:
75Description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 10.01 | |||||
Equity-to-Asset | -0.51 | |||||
Debt-to-Equity | -0.08 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.19 | |||||
Beneish M-Score | -5.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -83.2 | |||||
3-Year EPS without NRI Growth Rate | -59.7 | |||||
3-Year FCF Growth Rate | 23.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.44 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.01 | |||||
9-Day RSI | 48.87 | |||||
14-Day RSI | 53.18 | |||||
3-1 Month Momentum % | 24.25 | |||||
6-1 Month Momentum % | -9.39 | |||||
12-1 Month Momentum % | -45.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.65 | |||||
Quick Ratio | 7.65 | |||||
Cash Ratio | 7.44 | |||||
Days Sales Outstanding | 173.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -72.1 | |||||
Shareholder Yield % | -4.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5144.51 | |||||
Net Margin % | -8550.65 | |||||
EBITDA Margin % | -5008.28 | |||||
FCF Margin % | -4359.1 | |||||
OCF Margin % | -4110.87 | |||||
ROA % | -43.23 | |||||
ROIC % | -44.41 | |||||
3-Year ROIIC % | -66.87 | |||||
ROC (Joel Greenblatt) % | -536.33 | |||||
ROCE % | -27.12 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 141.17 | |||||
EV-to-EBIT | -1.87 | |||||
EV-to-EBITDA | -1.93 | |||||
EV-to-Revenue | 96.43 | |||||
EV-to-Forward-Revenue | 213.99 | |||||
EV-to-FCF | -2.21 | |||||
Price-to-GF-Value | 33.89 | |||||
Price-to-Median-PS-Value | 8.11 | |||||
Earnings Yield (Greenblatt) % | -53.48 | |||||
FCF Yield % | -27.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNAC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cartesian Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.775 | ||
| EPS (TTM) ($) | -5.91 | ||
| Beta | 0.4345 | ||
| 3-Year Sharpe Ratio | -0.22 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 64.95 | ||
| 14-Day RSI | 53.18 | ||
| 14-Day ATR ($) | 0.901655 | ||
| 20-Day SMA ($) | 9.674 | ||
| 12-1 Month Momentum % | -45.13 | ||
| 52-Week Range ($) | 5.6 - 14.56 | ||
| Shares Outstanding (Mil) | 29.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cartesian Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cartesian Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 27 days | ||
| General meeting for 2026 | 2026-06-12 10:00 | 8.06 (+8.63%) | ||
| H.C. Wainwright 4(th) Annual BioConnect Investor Conference | 2026-05-19 15:00 | 6.89 (-6.26%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 6.47 (-4.01%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 09:30 | 5.98 (-3.39%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 10:00 | 6.85 (-0.72%) | ||
| Annual report for 2025 | 2026-03-09 | 6.85 (-0.72%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 6.85 (-0.72%) | ||
| 46th Annual TD Cowen Health Care Conference | 2026-03-02 11:50 | 7.59 (-7.21%) |
Show
Entries
Cartesian Therapeutics Inc Frequently Asked Questions
What is Cartesian Therapeutics Inc(RNAC)'s stock price today?
The current price of RNAC is $9.49. The 52 week high of RNAC is $14.56 and 52 week low is $5.60.
When is next earnings date of Cartesian Therapeutics Inc(RNAC)?
The next earnings date of Cartesian Therapeutics Inc(RNAC) is 2026-08-07 Est..
Does Cartesian Therapeutics Inc(RNAC) pay dividends? If so, how much?
Cartesian Therapeutics Inc(RNAC) does not pay dividend.
Guru Commentaries on NAS:RNAC
No articles.
Press Release
Articles on Cartesian Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers